• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

AdDIT

ADOLESCENT TYPE 1 DIABETES CARDIO-RENAL INTERVENTION TRIAL

  • Home
  • Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT)
  • How we did it
  • AdDIT Cardiovascular Assessments
  • AdDIT Results
  • AdDIT Funders
  • Contact AdDIT UK
  • Co-ordinating Centres
  • AdDIT Follow Up
  • AdDIT Follow Up active sites
  • AdDIT Publications
  • Background to AdDIT
You are here: Home / Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT) / How we did it

How we did it

We established a central coordinating site in the UK and national coordinating sites in Australia and Canada.  A total of 32 subsidiary sites were established across the three countries.

UK Participating Sites

Click to expand

Australian participating sites

Click to expand

Canadian participating sites

Click to expand

We screened 4,407 young people with type 1 diabetes (age 10 – 16 years) across three countries (UK, Australia, Canada) to take part  in AdDIT, each providing six early morning urine samples (2 sets of 3) which were tested for protein levels (albumin). The amount of protein in the urine is a good indicator of renal function (the lower the better) and is a predictor for the future risk of kidney, retinal and heart complications.

Allocated

Based on the level of protein measured in their urine samples, we then allocated those screened to one of three  risk groups (tertiles): upper, middle and lower.

Recruited

Those young people with higher than average protein levels (upper tertile) were invited into the intervention study, to help us investigate if ACE inhibitors (blood pressure) or statin (Cholesterol lowering) drug therapy in young people reduces their future risk for complications.

We conducted what is called a double-blind placebo controlled trial. This meant that, neither the participants nor the doctors or nurses knew if they were taking an active drug or a placebo (dummy) drug. To decide which combination of tablets participants would take, we randomised each to one of four groups (see Figure 1 below).

 Young people who were at low risk, (middle and lower tertiles) of developing complications of diabetes were invited to join the observation study, to provide data that could be compared with those in the high risk group and help understanding risk factors and mechanisms implicated in the development of complications of diabetes.

Figure 1

Data collection

We then followed up participants for a minimum of 2 years and maximum of 4 years. Study visits were planned, where possible to coincide with regular clinic visits and we collected a range of data including; blood and urine samples, height, weight, blood pressure, safety data, cIMT scans, retinal photos.

 

 

 

 

Primary Sidebar

Contact Us

Social

A Twitter List by AdDIT2017

Footer

Co-ordinating Centres

Cookie and Privacy Policy

Site Map

  • Home
  • Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial (AdDIT)
  • How we did it
  • AdDIT Cardiovascular Assessments
  • AdDIT Results
  • AdDIT Funders
  • Contact AdDIT UK
  • Co-ordinating Centres
  • AdDIT Follow Up
  • AdDIT Follow Up active sites
  • AdDIT Publications
  • Background to AdDIT

Copyright © 2021  AdDIT Trial · Contact Form . Hosted by CSCS

Copyright © 2021 · Milan Pro on Genesis Framework · WordPress · Log in

  • Twitter